Sorafenib and cisplatin plus gemcitabine currently represent first-line treatment standards in
advanced hepatocellular carcinoma and biliary cancer, respectively. Conventional cytotoxic …

Purpose Sorafenib is considered a standard of care in advanced hepatocellular carcinoma
(HCC). Its combination with gemcitabine, a pyrimidine analogue with limited friendly hepatic …

After years of therapeutic nihilism due to the inefficacy of conventional cytotoxic
chemotherapy, the multikinase inhibitor sorafenib was the first agent to demonstrate a …

Liver cancer is the sixth most commonly diagnosed cancer and accounts for the fourth
leading cause of cancer-related death worldwide. 1 Hepatocellular carcinoma (HCC) is by …

Hepatocellular carcinoma (HCC) is the third leading cause of cancer death globally, and its
prevalence and impact are even more profound because sorafenib is the only systemic …

Advanced hepatocellular carcinoma (aHCC) is a complex disease beset by underlying liver
dysfunction and high molecular heterogeneity. Sorafenib, introduced in 2007, is considered …

Background Sorafenib is the only FDA-approved systemic therapy for advanced
hepatocellular carcinoma (HCC). In clinical practice, dose reductions are often required …

To date, sorafenib, a multiple tyrosine kinase inhibitor, is the only systemic agent approved
by the FDA in the first-line treatment of patients with unresectable hepatocellular carcinoma …

hepatocellular carcinoma (HCC) is the sixth most common malignancy worldwide and over
half a million cases are diagnosed annually. the prognosis for patients with unresectable or …

Background No standard second-line treatments are available for hepatocellular carcinoma
patients who fail sorafenib therapy. We assessed the safety and efficacy of metronomic …